- Home
- YHC vs PMCB Comparison
YHC vs PMCB Comparison
Compare YHC & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YHC
- PMCB
- Stock Information
- Founded
- YHC 2021
- PMCB 1996
- Country
- YHC United States
- PMCB United States
- Employees
- YHC N/A
- PMCB N/A
- Industry
- YHC Beverages (Production/Distribution)
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- YHC Consumer Staples
- PMCB Health Care
- Exchange
- YHC Nasdaq
- PMCB Nasdaq
- Market Cap
- YHC 12.3M
- PMCB 11.4M
- IPO Year
- YHC N/A
- PMCB N/A
- Fundamental
- Price
- YHC $1.15
- PMCB $1.76
- Analyst Decision
- YHC Strong Buy
- PMCB
- Analyst Count
- YHC 2
- PMCB 0
- Target Price
- YHC $5.00
- PMCB N/A
- AVG Volume (30 Days)
- YHC 113.4K
- PMCB 27.2K
- Earning Date
- YHC 03-31-2025
- PMCB 03-17-2025
- Dividend Yield
- YHC N/A
- PMCB N/A
- EPS Growth
- YHC N/A
- PMCB N/A
- EPS
- YHC N/A
- PMCB 0.74
- Revenue
- YHC $2,272,001.00
- PMCB N/A
- Revenue This Year
- YHC $120.06
- PMCB N/A
- Revenue Next Year
- YHC $72.42
- PMCB N/A
- P/E Ratio
- YHC N/A
- PMCB $2.37
- Revenue Growth
- YHC 158.05
- PMCB N/A
- 52 Week Low
- YHC $0.40
- PMCB $1.39
- 52 Week High
- YHC $2.45
- PMCB $2.58
- Technical
- Relative Strength Index (RSI)
- YHC N/A
- PMCB 60.08
- Support Level
- YHC N/A
- PMCB $1.57
- Resistance Level
- YHC N/A
- PMCB $1.66
- Average True Range (ATR)
- YHC 0.00
- PMCB 0.12
- MACD
- YHC 0.00
- PMCB 0.02
- Stochastic Oscillator
- YHC 0.00
- PMCB 68.89
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.